Efmarodocokin alfa

Generic Name: Efmarodocokin alfa

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1953227-87-6

Unique Ingredient Identifier: NYZ11835VX

Background: Efmarodocokin alfa is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1

Completed

Conditions: Acute Graft-versus-host Disease

Interventions: Drug: Efmarodocokin Alfa

First Posted Date: 2020-09-07

Last Posted Date: 2024-04-11

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 18

Registration Number: NCT04539470

Locations: 🇺🇸
University of Kansas Med Ctr; Int med/Allgy/Immun/Rheum, Kansas City, Kansas, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

and more 5 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy